Abstract 75P
Background
As part of key subgroup analyses of EMPOWER-lung 3 (NCT03409614), a double-blinded, randomized (2:1) phase 3 trial, an improvement in overall survival (OS) was observed with cemiplimab + chemotherapy (CEMI+CHEMO, n=47) vs placebo + chemotherapy (CHEMO, n=23) in patients with baseline liver metastases from advanced NSCLC (median OS: 14.4 vs 8.9 months; hazard ratio (HR): 0.61 (95% confidence interval (CI): [0.31, 1.20]). The safety results of patients with baseline liver metastases were generally similar to those of the overall study population. We conducted exploratory analyses to evaluate PROs within this subgroup of patients.
Methods
PROs were assessed at day 1 (baseline), the start of each treatment cycle (every 3 weeks) for the first 6 doses, and then at start of every third cycle, using the EORTC-QLQ-C30 and -QLQ-LC13 questionnaires. A mixed-effect model for repeated measures analysis was performed to compare CEMI+CHEMO vs CHEMO for all scales. Time to definitive clinically meaningful deterioration (TTD) was evaluated using Kaplan-Meier analysis and between-arm TTD comparisons were made using a log-rank test and proportional hazards model.
Results
Statistically significant delay in TTD was observed favouring CEMI+CHEMO over CHEMO for role functioning (HR: 0.28, 95% CI [0.10, 0.79]; p=0.011), cognitive functioning (0.18, [0.06, 0.55]; p=0.001), haemoptysis (<0.01, [<0.01, not calculable]); p=0.021), and alopecia (0.25, [0.09, 0.72]; p=0.007). When comparing between arms, no statistically significant differences between CEMI+CHEMO vs CHEMO in overall change from baseline across all C30 or LC13 scales were observed. No analyses yielded statistically significant PRO results favouring CHEMO vs CEMI+CHEMO for any C30 or LC13 scales.
Conclusions
Among patients with baseline liver metastases from advanced NSCLC, CEMI+CHEMO resulted in significant delay in TTD in role functioning, cognitive functioning, haemoptysis, and alopecia when compared with CHEMO. Overall change from baseline across all PROs were maintained. These PRO results further support the favourable benefit–risk profile of CEMI+CHEMO vs CHEMO in advanced NSCLC with baseline liver metastases.
Clinical trial identification
NCT03409614.
Editorial acknowledgement
Editorial support was provided by John G Facciponte, PhD, of Prime, Knutsford, UK.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc., and Sanofi.
Disclosure
A. Baramidze: Other, Personal, Other, Travel support: Regeneron Pharmaceuticals, Inc. C. Gessner: Financial Interests, Personal, Advisory Board: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, GSK, Novartis, Merck Sharp & Dohme, Pfizer, Roche, Sanofi. A. Sezer: Financial Interests, Institutional, Funding: Roche, Merck Sharp & Dohme, Merck Serono, AstraZeneca, Lilly, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Inc., Sanofi. M. Gumus: Financial Interests, Personal, Other, Honoraria: Roche, Merck Sharp & Dohme, Gen İlaç, Novartis. X. He, G. Gullo, P. Rietschel, R. Quek: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
181P - Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Presenter: Jitka Palich Fucikova
Session: Poster Display
182P - Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer
Presenter: Louisa Hell
Session: Poster Display
183P - Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1_/EMT Modulation
Presenter: Songwei Feng
Session: Poster Display
184P - Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study.
Presenter: LUCIA CARRIL AJURIA
Session: Poster Display
185P - The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma
Presenter: Yazan Al Zu’bi
Session: Poster Display
186P - Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: an EORTC IMMUcan sub-project
Presenter: Athénaïs Van Der Elst
Session: Poster Display
187P - Local and systemic anti-tumor response during tumor development in an immune privileged site: the case of uveal melanoma
Presenter: Francesca Lucibello
Session: Poster Display
188P - Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment
Presenter: Raya Leibowitz-Amit
Session: Poster Display
189P - The impact of immune microenvironment subopopulations on soft tissue sarcomas
Presenter: Shokhrukhbek Khujaev
Session: Poster Display